menu search

SEEL / Seelos tumbles 66% as depression drug fails after it recruits too few patients

Seelos tumbles 66% as depression drug fails after it recruits too few patients
Seelos Therapeutics (NASDAQ:SEEL) Inc's share price plummeted by 66% pre-market after the company announced that its phase II study for SLS-002, a treatment for adults with major depressive disorder at risk of suicide, failed to meet its primary goal. The primary goal, or "endpoint," is a key measure used to determine the success of a treatment in clinical trials. Read More
Posted: Sep 20 2023, 08:33
Author Name: Proactive Investors
Views: 110666

SEEL News  

Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023

By PRNewsWire
October 27, 2023

Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023

-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's disease, Huntington's disease, Amyotroph more_horizontal

Why Is Seelos Therapeutics (SEEL) Stock Down 25% Today?

By InvestorPlace
September 21, 2023

Why Is Seelos Therapeutics (SEEL) Stock Down 25% Today?

Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Thursday after the company released results from a clinical trial. Seelos Therapeutics first more_horizontal

Seelos tumbles 66% as depression drug fails after it recruits too few patients

By Proactive Investors
September 20, 2023

Seelos tumbles 66% as depression drug fails after it recruits too few patients

Seelos Therapeutics (NASDAQ:SEEL) Inc's share price plummeted by 66% pre-market after the company announced that its phase II study for SLS-002, a tre more_horizontal

Seelos Therapeutics' stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpoint

By Market Watch
September 20, 2023

Seelos Therapeutics' stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpoint

Seelos Therapeutics Inc.'s stock SEEL tumbled 36% in premarket trade Wednesday, after the company reported promising results from a trial of a treatme more_horizontal

Seelos: 2 Catalysts Before End Of 2023 Make This A Must Watch

By Seeking Alpha
July 12, 2023

Seelos: 2 Catalysts Before End Of 2023 Make This A Must Watch

Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideation and behavior for MDD, are expected to be rel more_horizontal

Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022

By PRNewsWire
December 8, 2022

Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022

NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the developme more_horizontal

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

By Zacks Investment Research
December 6, 2022

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Atai, Biogen, and Sage are working to develop new treatments for mental illness. more_horizontal


Search within

Pages Search Results: